Ref (type)	Population	Outcome, Interventions	Results and statistical analysis	Effect size	Favours
Symptom severity
RCT	306 treatment-resistant people	Clinical Global Impression scale (CGI) Severity scores 6 weeks with ziprasidone (80–160 mg/day) with chlorpromazine (200–1200 mg/day) Absolute results not reported	P less-than or equal to 0.05	Effect size not calculated	ziprasidone
RCT	306 treatment-resistant people	Positive and Negative Syndrome Scale (PANSS) negative subscale scores 12 weeks with ziprasidone (80–160 mg/day) with chlorpromazine (200–1200 mg/day) Absolute results not reported	P <0.05	Effect size not calculated	ziprasidone
RCT	306 treatment-resistant people	Brief Psychiatric Rating Scale (BPRS) score of 20% or more 12 weeks 58% with ziprasidone (80–160 mg/day) 55% with chlorpromazine (200–1200 mg/day) Absolute numbers not reported	Reported as not significant P value not reported		Not significant
RCT	306 treatment-resistant people	PANSS total score 12 weeks with ziprasidone (80–160 mg/day) with chlorpromazine (200–1200 mg/day) Absolute results not reported	Reported as not significant P value not reported		Not significant